MedPath

Fluconazole

Generic Name
Fluconazole
Brand Names
Diflucan
Drug Type
Small Molecule
Chemical Formula
C13H12F2N6O
CAS Number
86386-73-4
Unique Ingredient Identifier
8VZV102JFY
Background

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.

Indication

Fluconazole can be administered in the treatment of the following fungal infections:

1) Vaginal yeast infections caused by Candida

2) Systemic Candida infections

3) Both esophageal and oropharyngeal candidiasis

4) Cryptococcal meningitis

5) UTI (urinary tract infection) by Candida

6) Peritonitis (inflammation of the peritoneum) caused by Candida

A note on fungal infection prophylaxis

Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.

A note on laboratory testing

Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.

Associated Conditions
Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis

A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2013-08-16
Last Posted Date
2017-06-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
36
Registration Number
NCT01924299
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

Phase 2
Completed
Conditions
Candidiasis, Vulvovaginal
Interventions
First Posted Date
2013-07-03
Last Posted Date
2018-08-01
Lead Sponsor
Viamet
Target Recruit Count
55
Registration Number
NCT01891331
Locations
🇺🇸

Healthcare Clinical Data, Inc, North Miami, Florida, United States

🇺🇸

Harborview ID Research Clinic, Seattle, Washington, United States

🇺🇸

SUNY Downstate Medical Center, Brooklyn, New York, United States

and more 4 locations

Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy

Phase 3
Completed
Conditions
Human Immunodeficiency Virus
Interventions
First Posted Date
2013-04-05
Last Posted Date
2016-04-20
Lead Sponsor
Anna Griffiths, MRC
Target Recruit Count
1805
Registration Number
NCT01825031
Locations
🇺🇬

Joint Clinical Research Centre, Mbale, Mbale, Uganda

🇰🇪

Moi University Clinical Research Centre, Eldoret, Kenya

🇰🇪

KEMRI Wellcome Trust Research Programme, Kilifi, Kenya

and more 5 locations

The Study Of Fluconazole For Vulvovaginal Candidiasis

Phase 3
Completed
Conditions
Vulvovaginal Candidiasis
Interventions
First Posted Date
2013-03-07
Last Posted Date
2021-07-19
Lead Sponsor
Pfizer
Target Recruit Count
157
Registration Number
NCT01806623
Locations
🇯🇵

Hayakawa Clinic, Osaka, Japan

🇯🇵

Mori Ladies Clinic, Fukuoka, Japan

🇯🇵

IZUMI Ladies' Clinic, Gifu, Japan

and more 7 locations

A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2013-01-21
Last Posted Date
2016-11-02
Lead Sponsor
Genentech, Inc.
Target Recruit Count
92
Registration Number
NCT01772290

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa

Phase 2
Conditions
Cryptococcal Meningitis
HIV
Interventions
Procedure: lumbar punctures
First Posted Date
2012-10-29
Last Posted Date
2016-07-12
Lead Sponsor
ANRS, Emerging Infectious Diseases
Target Recruit Count
41
Registration Number
NCT01715922
Locations
🇧🇮

Hôpital général, Muyinga, Burundi

🇨🇮

Service de Maladies Infectieuses & Tropicales - Hôpital Triechville, Abidjan, Côte D'Ivoire

🇧🇮

CHU Kamenge, Bujumbura, Burundi

and more 2 locations

Pharmacokinetic Study of Fluconazole in Premature Infants

Phase 2
Completed
Conditions
Very Low Birth Weight Infant
Interventions
First Posted Date
2012-09-12
Last Posted Date
2014-11-19
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
80
Registration Number
NCT01683760
Locations
🇰🇷

Seoul National University Children's Hospital, Seoul, Korea, Republic of

Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis Medication

Completed
Conditions
Deep Mycosis
Interventions
First Posted Date
2012-09-07
Last Posted Date
2021-07-19
Lead Sponsor
Pfizer
Target Recruit Count
30
Registration Number
NCT01680458

Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection

Phase 2
Terminated
Conditions
Cryptococcal Infection Disseminated
Interventions
First Posted Date
2012-03-23
Last Posted Date
2021-09-29
Lead Sponsor
Yale University
Target Recruit Count
6
Registration Number
NCT01562132
Locations
🇰🇪

Family AIDS Care and Education Services, Sindo, Nyanza, Kenya

Operational Research for Cryptococcal Antigen Screening

Phase 4
Completed
Conditions
Cryptococcal Meningitis
Cryptococcus Neoformans
Cryptococcosis
Interventions
First Posted Date
2012-02-17
Last Posted Date
2020-06-04
Lead Sponsor
University of Minnesota
Target Recruit Count
3049
Registration Number
NCT01535469
Locations
🇺🇬

Infectious Disease Institute, Makerere University, Kampala, Uganda

🇺🇬

Kampala Capital Council Authority Clinics, Kampala, Uganda

© Copyright 2025. All Rights Reserved by MedPath